{"url_path":"/sec/ctkb/8-k/2026-06-25/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-25","source_url":"https://www.sec.gov/Archives/edgar/data/1831915/0001193125-26-282871-index.html","accession_number":"0001193125-26-282871","cik":"0001831915","ticker":"CTKB","issuer_name":"Cytek Biosciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1831915/0001193125-26-282871-index.html","primary_entity_key":"0001831915","primary_entity_name":"Cytek Biosciences, Inc."},"word_count":122,"has_tables":true,"body_markdown":"Item 5.02\n\nDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.\n\n(b)\n\nOn June 18, 2026, Valerie Barnett and Cytek Biosciences, Inc. (the “Company”) agreed that Ms. Barnett’s position as Chief Legal Officer and Corporate Secretary of the Company would terminate effective as of June 29, 2026. Ms. Barnett’s separation is not due to any disagreement with the Company’s operations, policies or practices.\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \nCytek Biosciences, Inc.\n\nDate: June 25, 2026\n \n\n \nBy:\n \n\n/s/ Wenbin Jiang\n\n \n\n \n\n \nWenbin Jiang, Ph.D.\n\n \n\n \n\n \nPresident and Chief Executive Officer"}